Immutep disclosed that its Phase III TACTI‑004 trial of eftilagimod alfa (efti) in first‑line non‑small‑cell lung cancer was halted for futility after an independent data monitoring committee review. The company said the interim analysis met stopping rules and it will wind down the study while it analyzes data to determine next steps. Immutep’s share price plunged on the news, reflecting investor concern about the program’s commercial and strategic viability. The TACTI‑004 readout was the most advanced test of efti to date and followed earlier positive signals in other tumor types, prompting surprise among analysts and management. Immutep said it will conduct a comprehensive review of the dataset to understand the discrepancy with prior trials and to evaluate potential paths forward for the LAG‑3 program. Regulatory or partnering options were not detailed at announcement.